BMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bristol-Myers Squibb Co (BMY) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. While the company shows some positive financial performance and pipeline potential, the lack of clear technical or trading signals, insider selling, and cautious sentiment from Congress and analysts suggest a hold position for now.
The technical indicators are mixed. The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 61.417, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Support and resistance levels suggest the stock is trading near its pivot point of 60.68, with resistance at 61.784 and support at 59.576.
Positive Phase 3 trial results for izalontamab brengitecan in triple-negative breast cancer.
Strong Q4 2025 financial performance, with revenue up 1.30% YoY, net income up 1409.72% YoY, and EPS up 1225.00% YoY.
Analysts see potential upside from the company's pipeline, particularly with Phase 3 catalysts in 2026.
Insider selling has increased significantly by 15753.10% over the last month.
Congress trading data shows 4 sale transactions and no purchases, indicating cautious sentiment.
Analysts have mixed ratings, with some highlighting risks such as the 'patent cliff' and macroeconomic factors.
The stock fell despite positive trial results, reflecting cautious market sentiment.
In Q4 2025, Bristol-Myers Squibb reported a revenue increase of 1.30% YoY to $12.5 billion. Net income surged by 1409.72% YoY to $1.087 billion, and EPS rose by 1225.00% YoY to $0.53. Gross margin improved to 65.34%, up 8.43% YoY, indicating strong profitability.
Analysts have mixed views. RBC Capital initiated coverage with a Sector Perform rating and a $60 price target, citing balanced risk-reward. Piper Sandler and Barclays are bullish, with price targets of $75, citing pipeline potential. However, Morgan Stanley remains bearish with an Underweight rating and a $40 price target. Overall, analysts are cautiously optimistic but highlight risks such as the 'patent cliff' and macroeconomic factors.
